Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Vanda rejects Future Pak and Cycle Pharma's takeover offers
09:40pm, Wednesday, 19'th Jun 2024
Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers underva
WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consulta
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
09:59pm, Monday, 17'th Jun 2024
Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline featur
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
09:00pm, Thursday, 13'th Jun 2024
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
10:02am, Thursday, 13'th Jun 2024
No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revis
Future Pak raises cash portion of buyout offer for Vanda
08:36am, Thursday, 13'th Jun 2024
Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.
Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.
08:15am, Thursday, 13'th Jun 2024
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Compan
SAN FRANCISCO--(BUSINESS WIRE)-- #assistivetechnology--CIONIC Unveils Three New Centers of Excellence to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation.
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
08:14am, Monday, 10'th Jun 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' poss
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
07:06am, Friday, 07'th Jun 2024
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
09:24am, Thursday, 06'th Jun 2024
No Shareholder Action Required at This Time WASHINGTON , June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsol
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
08:00am, Thursday, 06'th Jun 2024
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle” or the “Company”), a rapidly growing pharmaceutical company focused on treatments for the underserved rare dise
Vanda Insights: Aramco share sale is not surprising
06:00am, Friday, 31'st May 2024
Vandana Hari, founder of Vanda Insights, says it'll be a "test of investor appetite."
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
05:20pm, Thursday, 30'th May 2024
WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
04:48pm, Thursday, 30'th May 2024
WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications fo
